| DTT Name |
HUMAN ERK activator kinase 2 (MEK2)
|
| Synonyms |
PRKMK2; MKK2; MEK 2; MAPKK 2; MAPK/ERK kinase 2; MAP kinase kinase 2; Dual specificity mitogenactivated protein kinase kinase 2; Dual specificity mitogen-activated protein kinase kinase 2 |
| Gene Name |
MAP2K2
|
| BioChemical Class |
Kinase
|
| UniProt ID |
|
| TTD ID |
|
| 3D Structure |
|
| EC Number |
EC 2.7.12.2
|
| Sequence |
MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQ
KAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQ
VLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRG
LAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQ
GTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRP
PGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADL
KMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV
|
| Function |
Activates the ERK1 and ERK2 MAP kinases. Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. |
| KEGG Pathway |
- EGFR tyrosine kinase inhibitor resistance (hsa01521 )
- Endocrine resistance (hsa01522 )
- MAPK signaling pathway (hsa04010 )
- ErbB signaling pathway (hsa04012 )
- Ras signaling pathway (hsa04014 )
- Rap1 signaling pathway (hsa04015 )
- cGMP-PKG signaling pathway (hsa04022 )
- cAMP signaling pathway (hsa04024 )
- HIF-1 signaling pathway (hsa04066 )
- FoxO signaling pathway (hsa04068 )
- Sphingolipid signaling pathway (hsa04071 )
- Phospholipase D signaling pathway (hsa04072 )
- Autophagy - animal (hsa04140 )
- mTOR signaling pathway (hsa04150 )
- PI3K-Akt signaling pathway (hsa04151 )
- Apoptosis (hsa04210 )
- Cellular senescence (hsa04218 )
- Vascular smooth muscle contraction (hsa04270 )
- VEGF signaling pathway (hsa04370 )
- Apelin signaling pathway (hsa04371 )
- Gap junction (hsa04540 )
- Signaling pathways regulating pluripotency of stem cells (hsa04550 )
- Neutrophil extracellular trap formation (hsa04613 )
- Toll-like receptor signaling pathway (hsa04620 )
- Natural killer cell mediated cytotoxicity (hsa04650 )
- T cell receptor signaling pathway (hsa04660 )
- B cell receptor signaling pathway (hsa04662 )
- Fc epsilon RI signaling pathway (hsa04664 )
- Long-term potentiation (hsa04720 )
- Neurotrophin signaling pathway (hsa04722 )
- Long-term depression (hsa04730 )
- Regulation of actin cytoskeleton (hsa04810 )
- Insulin signaling pathway (hsa04910 )
- GnRH signaling pathway (hsa04912 )
- Estrogen signaling pathway (hsa04915 )
- Melanogenesis (hsa04916 )
- Prolactin signaling pathway (hsa04917 )
- Thyroid hormone signaling pathway (hsa04919 )
- Oxytocin signaling pathway (hsa04921 )
- Relaxin signaling pathway (hsa04926 )
- GnRH secretion (hsa04929 )
- Cushing syndrome (hsa04934 )
- Growth hormone synthesis, secretion and action (hsa04935 )
- Alzheimer disease (hsa05010 )
- Pathways of neurodegeneration - multiple diseases (hsa05022 )
- Salmonella infection (hsa05132 )
- Yersinia infection (hsa05135 )
- Hepatitis C (hsa05160 )
- Hepatitis B (hsa05161 )
- Human cytomegalovirus infection (hsa05163 )
- Influenza A (hsa05164 )
- Human papillomavirus infection (hsa05165 )
- Human T-cell leukemia virus 1 infection (hsa05166 )
- Kaposi sarcoma-associated herpesvirus infection (hsa05167 )
- Human immunodeficiency virus 1 infection (hsa05170 )
- Pathways in cancer (hsa05200 )
- Proteoglycans in cancer (hsa05205 )
- MicroRNAs in cancer (hsa05206 )
- Chemical carcinogenesis - receptor activation (hsa05207 )
- Chemical carcinogenesis - reactive oxygen species (hsa05208 )
- Colorectal cancer (hsa05210 )
- Renal cell carcinoma (hsa05211 )
- Endometrial cancer (hsa05213 )
- Glioma (hsa05214 )
- Prostate cancer (hsa05215 )
- Thyroid cancer (hsa05216 )
- Melanoma (hsa05218 )
- Bladder cancer (hsa05219 )
- Chronic myeloid leukemia (hsa05220 )
- Acute myeloid leukemia (hsa05221 )
- Non-small cell lung cancer (hsa05223 )
- Breast cancer (hsa05224 )
- Hepatocellular carcinoma (hsa05225 )
- Gastric cancer (hsa05226 )
- Central carbon metabolism in cancer (hsa05230 )
- Choline metabolism in cancer (hsa05231 )
- PD-L1 expression and PD-1 checkpoint pathway in cancer (hsa05235 )
|
| Reactome Pathway |
- Frs2-mediated activation (R-HSA-170968 )
- Signal transduction by L1 (R-HSA-445144 )
- Uptake and function of anthrax toxins (R-HSA-5210891 )
- RAF activation (R-HSA-5673000 )
- MAP2K and MAPK activation (R-HSA-5674135 )
- Negative feedback regulation of MAPK pathway (R-HSA-5674499 )
- Signaling by moderate kinase activity BRAF mutants (R-HSA-6802946 )
- Signaling by high-kinase activity BRAF mutants (R-HSA-6802948 )
- Signaling by BRAF and RAF1 fusions (R-HSA-6802952 )
- Paradoxical activation of RAF signaling by kinase inactive BRAF (R-HSA-6802955 )
- Signaling downstream of RAS mutants (R-HSA-9649948 )
- Signaling by MAP2K mutants (R-HSA-9652169 )
- Signaling by RAF1 mutants (R-HSA-9656223 )
- MAPK1 (ERK2) activation (R-HSA-112411 )
|
|
|
|
|
|
|
